Want to see NSRX full AI Analyst Report?
Nasus Pharma Ltd. (NSRX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Epinephrine 4Mg Nasal Powder Spray, Adrenalin 0.5Mg Injectable Product | Anaphylaxis Food | phase2AndPhase3 | Enrolling By Invitation | FMXIN002 in Patients at Risk of Anaphylaxis | Jun 08, 2025 | ― |
| A: Epinephrine Injection, B: Fmxin002 3.6Mg, C: Fmxin002 4.0Mg | Anaphylaxis, Anaphylactic Reaction | phase1AndPhase2 | Completed | Comparative Bioavailability of Intranasal Epinephrine | Dec 18, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Epinephrine 4Mg Nasal Powder Spray, Adrenalin 0.5Mg Injectable Product | phase2AndPhase3 | Anaphylaxis Food | Enrolling By Invitation | FMXIN002 in Patients at Risk of Anaphylaxis | Jun 08, 2025 | ― |
| A: Epinephrine Injection, B: Fmxin002 3.6Mg, C: Fmxin002 4.0Mg | phase1AndPhase2 | Anaphylaxis, Anaphylactic Reaction | Completed | Comparative Bioavailability of Intranasal Epinephrine | Dec 18, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nasus Pharma Ltd. (NSRX) have in its pipeline
Nasus Pharma Ltd. NSRX is currently developing the following drugs: Epinephrine 4Mg Nasal Powder Spray, Adrenalin 0.5Mg Injectable Product, A: Epinephrine Injection, B: Fmxin002 3.6Mg, C: Fmxin002 4.0Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.